NCT04231747
Clinical Trial Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04231747
Title A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Juno Therapeutics, a Subsidiary of Celgene
Indications
diffuse large B-cell lymphoma
follicular lymphoma
marginal zone lymphoma
B-cell lymphoma
primary mediastinal B-cell lymphoma
Therapies
CC-97540
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Local Institution - 003 Birmingham Alabama 35294-3300 United States Details
Local Institution - 004 Atlanta Georgia 30342 United States Details
Local Institution - 011 Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Nebraska Medicine Fred and Pamela Buffett Cancer Center Omaha Nebraska 68105 United States Details
Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Local Institution - 001 New York New York 10021 United States Details
Local Institution - 008 New York New York 10065 United States Details
Local Institution - 010 Charlotte North Carolina 28204 United States Details
Oregon Health and Science University OHSU Portland Oregon 97239 United States Details
Huntsman Cancer Institute - University of Utah Salt Lake City Utah 84112 United States Details
Foothills Medical Centre - Tom Baker Cancer Centre Calgary Alberta T2N 2T9 Canada Details
Vancouver General Hospital Vancouver British Columbia V5Z 1M9 Canada Details
Juravinski Cancer Centre Hamilton Ontario L8V 1C3 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field